Fish oil formula could tame inflammation in rare lung disease
NCT ID NCT07697235
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This study tests whether a specially formulated omega-3 supplement, with a high ratio of EPA to DHA, can reduce inflammation and improve blood vessel function in people with pulmonary arterial hypertension (PAH). Participants take four capsules daily for 12 weeks alongside their usual PAH medications. The goal is to see if this nutritional approach can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Omega-3 fatty acids (EPA and DHA in a 6:1 ratio)
- What this could lead to
- If successful, this could point toward a simple nutritional supplement to help manage inflammation and blood vessel health in people with PAH.
- What could go wrong
- This is a small, early-stage study with only 22 participants, so results may not apply to everyone. The supplement is tested alongside standard care, not as a replacement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 22 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men or women between the ages of 18 and 75; * Idiopathic, hereditary, drug-induced, or anorexigen-induced PAH, or PAH associated with connective tissue disease; * Stable PAH treatment for at least 90 days; * Subjects capable of understanding the objectives and risks associated with the study and of providing dated and signed informed consent; * Subjects enrolled in a health insurance plan; * Subjects who have signed an informed consent form; * For women of childbearing age: negative pregnancy test at the screening/inclusion visit; effective contraception\* throughout the study (recommended in PAH) * Effective and accepted methods of contraception during the study (subject, partner): oral contraceptive pill, intrauterine device (IUD), condom (male or female). Patients who practice total abstinence do not need to use contraception. Exclusion criteria: * Patients treated with Omacor®; * Daily consumption of fish oil or fish oil-based dietary supplements (omega-3); * Hypersensitivity or allergy to fish, shellfish, peanuts, soy, corn oil, or coconut oil; * Anticoagulant therapy at therapeutic doses; * Cardiac decompensation within the month prior to enrollment; * Other causes of pulmonary hypertension (groups 2, 3, 4, or 5); * Persistent atrial fibrillation (AF); * Left ventricular ejection fraction \< 45% on echocardiography; * Recent episode of pulmonary embolism, within the past 6 months; * Myocardial infarction or placement of a coronary stent within the month prior to enrollment; * eGFR \< 30 mL/min/1.73 m²; * Malignant disease (not considered in remission); * Severe sepsis; * Participation in another clinical trial within the previous 3 months; * Subjects under legal guardianship, conservatorship, or curatorship
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAH are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.